The First Hospital Of Jilin University
Clinical trials sponsored by The First Hospital Of Jilin University, explained in plain language.
-
AI takes on diabetes: smartphone app could revolutionize blood sugar control
Disease control Recruiting nowThis study tests whether an artificial intelligence (AI) smartphone app can help people with type 2 diabetes control their blood sugar better than standard doctor visits. About 400 adults will use the app to get personalized advice on medication, diet, and exercise. The goal is t…
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 16, 2026 23:53 UTC
-
New drug combo aims to slow kidney disease in IgA patients
Disease control Recruiting nowThis study tests whether combining budesonide and ambrisentan can lower protein in the urine and slow kidney function loss in people with IgA nephropathy, a chronic kidney disease. About 129 adults aged 18–70 with protein in their urine will receive the combo for 36 weeks. The go…
Phase: PHASE4 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 16, 2026 23:52 UTC
-
Less food before flip: new study aims to reduce stomach trouble in ICU lung patients
Disease control Recruiting nowThis study looks at whether reducing the amount of liquid food given through a tube before turning patients onto their stomach (prone position) can lower the risk of stomach problems like bloating and vomiting. The trial will include 259 adults with severe lung failure who are on…
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 16, 2026 23:51 UTC
-
New hope for hard-to-treat ovarian cancer: experimental combo enters human trial
Disease control Recruiting nowThis study tests whether adding an experimental drug called CapsuleX to standard cisplatin chemotherapy can shrink tumors in people with ovarian cancer that no longer responds to platinum-based drugs. About 40 adults with recurrent ovarian, fallopian tube, or primary peritoneal c…
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
New hope for tough colorectal cancer: Second-Line combo trial launches
Disease control Recruiting nowThis study tests a new combination of drugs for people with advanced colorectal cancer that has stopped responding to initial treatment. About 30 adults aged 18-75 will receive a mix of chemotherapy and targeted therapy. The goal is to see if this approach can slow or stop cancer…
Phase: PHASE2 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
Supercharged immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy, boosted with a protein called IL-15, in people with multiple myeloma or plasma cell leukemia that has come back or not responded to treatment. The goal is to see if these enhanced immune cells can shrink or eliminate the cancer. …
Phase: PHASE2 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
New combo therapy aims to keep advanced ovarian cancer at bay
Disease control Recruiting nowThis study tests whether adding daphnetin capsules to standard chemotherapy and targeted therapy can help control advanced ovarian cancer after initial surgery. About 98 participants with stage III-IV ovarian cancer will receive the treatment and be monitored for side effects and…
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New surgery may help rectal cancer patients avoid a permanent bag
Disease control Recruiting nowThis study tests if a newer two-step surgery (Turnbull-Cutait) helps people with low rectal cancer avoid a permanent stoma (colostomy bag) better than standard surgery with a temporary stoma. About 520 adults with low rectal cancer will be randomly assigned to one of the two surg…
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy aims to shrink high-risk rectal tumors before surgery
Disease control Recruiting nowThis study is for people with mid-to-low rectal cancer that has high-risk features. It compares two treatment plans: short-course radiation followed by chemotherapy plus an immunotherapy drug (toripalimab), with or without an additional anti-angiogenic drug (surufatinib). The goa…
Phase: PHASE2, PHASE3 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Could a second drug boost stroke recovery? new trial aims to find out.
Disease control Recruiting nowThis study tests whether giving the blood-thinner tirofiban soon after standard clot-busting therapy helps people recover better from a stroke. About 1,084 adults who had a moderate-to-severe stroke will receive either tirofiban or a placebo within 6 hours of the initial treatmen…
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New drug combo aims to keep rare skin cancer from returning
Disease control Recruiting nowThis study is for people with a rare type of skin cancer called mucosal melanoma that has been completely removed by surgery and tests positive for PD-L1. The trial compares the effects of adding the immunotherapy drug sintilimab to standard chemotherapy versus chemotherapy alone…
Phase: PHASE2 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
New antibacterial liquid aims to clear stubborn HPV infections
Disease control Recruiting nowThis study is testing whether an antibacterial liquid called Paiteling can help clear persistent high-risk HPV infections in the cervix. It involves 115 women aged 25 to 65 who have had the same high-risk HPV type for at least two years. The main goal is to see if the infection t…
Phase: PHASE4 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New ultrasound combo may spot deadly vein bleeding risk without a scope
Diagnosis Recruiting nowThis study tests a new, non-invasive way to find high-risk varices (enlarged veins) in the stomach and esophagus of people with liver cirrhosis. Instead of using a scope, doctors will combine a special ultrasound technique with liver stiffness measurements and a simple blood plat…
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Diagnosis
Last updated May 14, 2026 12:06 UTC
-
AI to predict dangerous clots after lung cancer surgery
Knowledge-focused Recruiting nowThis study looks at why some people develop dangerous blood clots (deep vein thrombosis) after lung cancer surgery. Researchers will follow 900 patients for 30 days after their operation, collecting medical data to find risk factors. They will then use machine learning to build a…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated May 16, 2026 23:47 UTC
-
New model aims to predict hidden polyps in kidney stone patients
Knowledge-focused Recruiting nowThis study is looking for risk factors that might lead to inflammatory polyps in the ureter (the tube from kidney to bladder) in people with kidney stones. Researchers will use past patient data to build a prediction model, then test it on new patients. The goal is to help doctor…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated May 14, 2026 12:06 UTC
-
Blood particle analysis may reveal clues about aneurysm rupture risk
Knowledge-focused Recruiting nowThis study looks at tiny particles called extracellular vesicles in the blood of people with brain aneurysms. Researchers want to see if the proteins in these particles differ depending on where in the body the blood is taken and whether the aneurysm has burst. About 120 adults w…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated May 11, 2026 20:46 UTC